We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
67 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)Eydenzelt (aflibercept) has been approved for the treatment in adults of visual impairment due to myopic choroidal neovascularisation.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMLYCLO omalizumab (rch) 75 mg/0.5 mL solution for injection pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMLYCLO omalizumab (rch) 150 mg/ mL solution for injection pre-filled pen.
-
Australian public assessment report (AusPar)OMLYCLO (omalizumab), a biosimilar to XOLAIR, is approved to treat allergic asthma, chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVTOZMA tocilizumab (rch) 162 mg/0.9 mL solution for injection pre-filled pen, AVTPen Autoinjector.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVTOZMA tocilizumab (rch) 162 mg/0.9 mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVTOZMA tocilizumab (rch) 400 mg/20 mL injection concentrated vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVTOZMA tocilizumab (rch) 80 mg/4 mL injection concentrated vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVTOZMA tocilizumab (rch) 200 mg/10 mL injection concentrated vial.
-
Cancellation by sponsorRequested by Celltrion Healthcare Australia Pty Ltd